Potential new drug targets to control cholesterol levels identifiedDecember 8th, 2008 - 2:17 pm ICT by ANI
London, Dec 8 (ANI): Scientists have identified potential new drug targets for managing cholesterol or triglyceride levels.
They have discovered 11 new sites in the human genome where common variations seem to influence cholesterol, bringing the total number of lipid-associated genes to 30.
While major mutations in some of these genes have been known to underlie rare lipid metabolism disorders, it is becoming apparent that common changes in the same genes that have modest effects can combine with risk-associated variants in other genes to significantly influence blood lipid levels.
“Finding new gene regions involved with lipid levels could improve our understanding of cholesterol regulation, help identify individuals who are at greater risk for heart disease, and point out new targets for drugs to control cholesterol levels, Nature quoted Sekar Kathiresan, MD, director of Preventive Cardiology at Massachusetts General Hospital (MGH), the paper’’s corresponding author, as saying.
Based on previous work that linked common variants at 19 locations to lipid levels, the researchers first conducted a meta-analysis of seven genome-wide association studies of blood lipid levels.
Potential lipid-associated sites identified in that first-phase analysis of data from almost 20,000 individuals including participants in the Framingham Heart Study, which first established blood cholesterol as a risk factor for heart disease in 1961 were then genotyped using DNA samples from another 20,600 participants in five different studies.
This validation phase found 30 gene sites, including the 19 previously identified, that were associated with levels of either high-density lipoprotein cholesterol, low-density lipoprotein cholesterol or triglycerides.
Rare mutations in some of the 11 newly identified genes have been known to cause serious cholesterol disorders or conditions like type 2 diabetes, but this study is the first to link common variations in those genes with cholesterol levels.
Others of the novel genes had no previous link to lipid metabolism. Some of them appear to be transcription factors, which control how other genes work, or enzymes that modify the molecules that transport cholesterol in the blood, but the function of others is still unknown.
“We”re finding that many of the variants that affect blood lipids seem to do so by influencing how much of a gene is expressed in the liver. With rare mutations, gene function is usually is completely abolished, but these common variants appear to affect the quantity but not necessarily the quality of protein being produced,” Kathiresan said.
The study will appear online in the journal Nature Genetics. (ANI)
- 95 genetic variants linked to heart disease identified - Aug 05, 2010
- Statin can prevent strokes, besides lowering lipids - Jan 05, 2012
- Additional genes linked to age-related macular degeneration identified - Apr 13, 2010
- Biomarker can nip hardening of arteries in the bud - Jan 22, 2012
- Scientists find 13 new genes linked to heart diseases - Mar 07, 2011
- Why some people develop medical complications of obesity while others don't - Mar 11, 2011
- Routine periodic fasting good for health, heart - Apr 04, 2011
- Increasing triglyceride level 'linked to high risk of stroke' - Feb 21, 2011
- Rare genes behind high triglyceride levels in blood identified - Jul 26, 2010
- Dark chocolate may reduce cardio risks, study shows - Apr 25, 2012
- Gene linked to high cholesterol in blood found - Sep 16, 2010
- Eat nuts to bring down cholesterol levels - May 11, 2010
- Gene network behind hardening arteries identified - Sep 19, 2010
- Scientists isolate genes behind BP, stroke, cardiac risks - Sep 12, 2011
- Features of metabolic syndrome prevalent in people with psoriasis - Dec 21, 2010
Tags: blood cholesterol, blood lipid levels, cholesterol disorders, cholesterol levels, density lipoprotein cholesterol, dna samples, drug targets, framingham heart study, gene regions, high density lipoprotein, human genome, lipid metabolism, low density lipoprotein, massachusetts general hospital, metabolism disorders, phase analysis, preventive cardiology, rare mutations, triglyceride levels, validation phase